New Bio-manufacturing Facility Launch Event
This week marks the official launch of Orthocell’s new GMP certified bio-manufacturing facility at the Company headquarters in Perth.
May 29, 2023
VIDEO | Proactive Investors – May 2023
Orthocell’s MD Paul Anderson and John Van Der Wielen spoke with Andrew Scott at Proactive Investors about John’s appointment as independent non-executive chairman. John brings 35 years of global experience in wealth management, private banking, investments and health insurance, including considerable experience in corporate strategy, international growth initiatives, M&A transactions and engaging strategic investors.
May 29, 2023
Veritas Securities Equity Research Report | April 2023
Veritas Securities Limited has released an Equity Research report valuing Orthocell (ASX: OCC) at A$0.90 per share. The report summarises the commercial potential of Orthocell’s novel orthopaedic repair technology and its advanced product pipeline, as well as the competitive advantages and revenue opportunities associated with its Striate™ and Remplir™ products – especially in the US. […]
April 26, 2023
Commencement of Nerve Repair Study
Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory and reimbursement strategies for its nerve repair device, Remplir. The comparator study aims to evaluate the safety, mechanism of action and product performance of Remplir™, when used as a nerve wrap in peripheral nerve repair, […]
April 18, 2023
The West Australian | WA training for the heavyweight fight
Orthocell (ASX $OCC) has been featured in a story titled “WA training for the heavyweight fight”, published in The West Australian’s Business section this weekend.
March 10, 2023
VIDEO | Proactive Investors – March 2023
Orthocell’s Paul Anderson spoke with Andrew Scott at Proactive Investors to discuss to discuss the announcement that the Company had secured Device Technologies as the exclusive distribution partner for Remplir™ in the Australian marketplace.
March 8, 2023
Finding the Front Podcast | February 2022
This week, Orthocell’s CEO and MD, Paul Anderson, joined Tim Banfield on Euroz Hartley’s Finding the Front Podcast.
February 20, 2023
Remplir™ Gains Australian Reimbursement
Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.
November 1, 2022
Stockhead Investor Guide | September 2022
Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.
September 30, 2022
Ortho-ATI™ Shoulder Tendon Study Update
Orthocell has today shared positive results from the crossover extension arm of our randomised clinical trial examining the performance of our OrthoATI™ therapy in the treatment of rotator cuff tendon injuries, compared to a steroid injection.
September 28, 2022